Long-Term Control of NMOSD With Ravulizumab

by Medscape • 2025/10/03 • 0 Comments

For neuromyelitis optica spectrum disorder, long-term follow-up with a second-generation complement inhibitor shows an unprecedented level of disease control at 3 years.
Medscape Medical News

← Perfect Corp. Releases Virtual Try-On for Glasses Update with New In-Platform Product Library Featuring Over 13,000 Pre-Loaded Glasses SKUs

Broadwood Partners Publishes Presentation Detailing Opposition to STAAR Surgical’s Sale to Alcon →